Drug
Imc C103c
Imc C103c: highest development phase Phase 1/2, developed by Immunocore. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Immunocore
Trials
| Drug | Phase | Indication |
|---|---|---|
| IMC-C103C NCT03973333 | Phase 1/2 | Select Advanced Solid Tumors |
Latest
No recent events.
Follow Imc C103c on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.